Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150798 | 1.00 | ADRB2 (0.49) | ADRB2CHRM3CHRM2CHRM1LTA4H | |
| SCHEMBL4141725 | 0.90 | ADRB2 (0.55) | ADRB2CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4657685 | 0.90 | ADRB2 (0.47) | ADRB2CHRM3CHRM2CHRM1LTA4H | |
| SCHEMBL4155144 | 0.89 | ADRB2 (0.64) | ADRB2CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4145088 | 0.89 | ADRB2 (0.64) | ADRB2CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4144944 | 0.89 | ADRB2 (0.48) | ADRB2CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4151178 | 0.89 | ADRB2 (0.56) | ADRB2CHRM3CHRM2CHRM1KCNH2 | |
| SCHEMBL4153782 | 0.87 | ADRB2 (0.57) | ADRB2CHRM3CHRM2CHRM1 | |
| SCHEMBL4157075 | 0.86 | ADRB2 (0.50) | ADRB2CHRM3CHRM2CHRM1BCHE | |
| SCHEMBL4154452 | 0.85 | CHRM3 (0.61) | ADRB2CHRM3CHRM2CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612084-B2 | Amine derivatives for the treatment of asthma and COPD | PFIZER INC (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| EP-1999107-A2 | AMINE DERIVATIVES | Pfizer Limited (GB) | 2008-12-10 | — | — | EP | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| WO-2007107828-A2 | AMINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265303-A1 | Amine derivatives | HNMT, HRH4, CMA1 | ADRB2 93/4885CHRM3 169/4885CHRM2 142/4885 |
| US-20090253739-A1 | Amine Derivatives | HNMT, HRH4, CMA1 | ADRB2 93/4885CHRM3 169/4885CHRM2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.